PMID- 31155578
OWN - NLM
STAT- MEDLINE
DCOM- 20191125
LR  - 20191125
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 42
IP  - 6
DP  - 2019
TI  - The Effective Allergenic Reactivity of House Dust Mite Sublingual Immunotherapy 
      Tablets Is Determined by Tablet Formulation.
PG  - 1030-1033
LID - 10.1248/bpb.b18-00857 [doi]
AB  - House dust mite (HDM) sublingual immunotherapy (SLIT) in the form of SLIT-tablets 
      is now an established treatment option for HDM allergy and HDM-induced allergic 
      asthma. In SLIT-tablet immunotherapy allergen extracts are formulated as dry 
      tablets and administered under the tongue where it must be solubilized in saliva 
      in order to be able to interact with the immune system of the sublingual mucosa. 
      Solubilization of the extract must occur within a short time span of about one 
      minute after administration, determined by the sublingual holding time 
      recommended by the manufacturer. Currently, two types of HDM SLIT-tablets are 
      available. Both tablet types contain natural HDM extracts from two common HDM 
      species as the active ingredient, but differ with regard to formulation as one 
      tablet type is based on a freeze-dried tablet formulation while the other is 
      based on a compressed formulation. HDM extracts contain a number of major and 
      minor allergens, which in combination provide the allergenic activity that drives 
      the immunological response and in turn the clinical efficacy of the tablets. 
      Here, a biologically relevant human immunoglobulin E (IgE)-based assay is used to 
      compare the ability of the two HDM SLIT-tablet types to deliver HDM allergenic 
      reactivity from the dry tablet into soluble form. The experiments demonstrate 
      that the freeze-dried formulation delivers HDM allergenic activity into solution 
      faster and more efficiently than the compressed formulation.
FAU - Kito, Hirokazu
AU  - Kito H
AD  - Research Laboratory, Torii Pharmaceutical Co., Ltd.
FAU - Du, Weibin
AU  - Du W
AD  - Research Laboratory, Torii Pharmaceutical Co., Ltd.
FAU - Nakazawa, Hiroshi
AU  - Nakazawa H
AD  - Research Laboratory, Torii Pharmaceutical Co., Ltd.
FAU - Lund, Kaare
AU  - Lund K
AD  - Papermill Medical.
FAU - Ohashi-Doi, Katsuyo
AU  - Ohashi-Doi K
AD  - Research Laboratory, Torii Pharmaceutical Co., Ltd.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Allergens)
RN  - 0 (Antigens, Dermatophagoides)
RN  - 0 (Tablets)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens/*immunology
MH  - Animals
MH  - Antigens, Dermatophagoides/*immunology
MH  - Drug Compounding
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - Pyroglyphidae/*immunology
MH  - *Sublingual Immunotherapy
MH  - *Tablets
OTO - NOTNLM
OT  - allergen-specific immunotherapy
OT  - allergenic reactivity
OT  - house dust mite
OT  - release kinetic
OT  - sublingual tablet
OT  - tablet formulation
EDAT- 2019/06/04 06:00
MHDA- 2019/11/26 06:00
CRDT- 2019/06/04 06:00
PHST- 2019/06/04 06:00 [entrez]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2019/11/26 06:00 [medline]
AID - 10.1248/bpb.b18-00857 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2019;42(6):1030-1033. doi: 10.1248/bpb.b18-00857.